Literature DB >> 6766290

Cost-effective care of end-stage renal disease: a billion dollar question.

S D Roberts, D R Maxwell, T L Gross.   

Abstract

We examined the survival time and costs of therapy for patients with end-stage renal disease. A computer simulation model of the current system was constructed to estimate the cost-effectiveness of home and center hemodialysis and live related as well as cadaver donor renal transplantation. Analysis of the simulation showed that live related donor transplantation was the least costly and had the greatest survival time, while center hemodialysis had the poorest cost-effectiveness. By simulating changes to the present system of care, we found that shifts from center dialysis to either home dialysis or cadaver donor transplantation would save $7000 to $8000 per life year, or $284 million per year for the existing end-stage renal disease population. However, if legislative changes fail to produce real shifts from center hemodialysis, costs will increase. We conclude that the substantial costs for end-stage renal disease can be contained by shifting from the widespread use of center hemodialysis.

Entities:  

Mesh:

Year:  1980        PMID: 6766290     DOI: 10.7326/0003-4819-92-2-243

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  10 in total

1.  Is there a role for free breathing non-contrast steady-state free precession renal MRA imaging for assessing live donors? A preliminary study.

Authors:  I Laurence; B Ariff; R A Quest; S Moser; A Glover; D Taube; P Gishen; V Papalois; C Juli
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

2.  The reliability of cost-utility estimates in cost-per-QALY league tables .

Authors:  S Petrou; M Malek; P G Davey
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

3.  Economic decision making in healthcare. A standard approach to discounting health outcomes.

Authors:  A L Hillman; M S Kim
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

Review 4.  Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.

Authors:  J E Frampton; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

5.  Using simulation to plan Health Service resources: discussion paper.

Authors:  R Davies; T Davies
Journal:  J R Soc Med       Date:  1986-03       Impact factor: 5.344

6.  Financial effect of clinical decisions: case study of a dialysis center.

Authors:  E A Balas; L L Hicks; J V Stone; L P Ponferrada; D A West
Journal:  J Med Syst       Date:  1995-12       Impact factor: 4.460

7.  Long-term survival after cadaveric renal transplantation.

Authors:  E Savdie; J F Mahony; R J Caterson; J H Stewart; S Etheredge; B G Storey; A G Sheil
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-23

8.  Reuse of haemodialysis equipment: convenience and cost effectiveness.

Authors:  H K Banester; R D Driscoll; R N Greenwood; W R Cattell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-14

Review 9.  Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease.

Authors:  J W Hay; W M Yu; T Ashraf
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.558

Review 10.  Challenges of organ shortage for transplantation: solutions and opportunities.

Authors:  R F Saidi; S K Hejazii Kenari
Journal:  Int J Organ Transplant Med       Date:  2014
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.